Physician profile
Michelle Bush
NPI 1679503270
$4,020.23
in general payments reported to CMS, 2019-2025
24 companies · $433 in 2025
The $433 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $58.35 · 2021: $82.33 · 2022: $142 · 2023: $382 · 2024: $2,303 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,118.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,451.69 | 2019-2025 | Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $512.12 | 2023-2024 | Sotyktu |
| Lilly USA, LLC | $364.90 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $281.89 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Amgen INC. | $218.47 | 2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $143.36 | 2019-2024 | Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $134.02 | 2019-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $125.50 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $115.97 | 2024-2025 | Dupixent |
| Celgene Corporation | $112.63 | 2019-2024 | Sotyktu |
| Genzyme Corporation | $108.81 | 2023-2024 | |
| Organon LLC | $96.77 | 2025 | Vtama |
| Incyte Corporation | $96.54 | 2022-2024 | Opzelura |
| Leo Pharma INC. | $64.49 | 2021 | |
| Dermira, INC. | $30.68 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dusa Pharmaceuticals, INC. | $24.39 | 2019 | |
| Pfizer INC. | $22.93 | 2019 | |
| Verrica Pharmaceuticals INC. | $21.63 | 2024 | Ycanth |
| Dermavant Sciences, INC. | $21.15 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $17.59 | 2025 | Zoryve |
| Ucb, INC. | $15.23 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.06 | 2024 | Nuzyra |
| Almirall LLC | $12.86 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Bush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.